ReviewFrontiers in public health2025
The future of multimorbidity management in the older adults: transforming AI-enabled precision medicine.
Review in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Co-occurrence network characteristics and key comorbidity node identification based on health examination indicators among rural older adults aged 65 and above.BMC geriatrics · 2026Article
- Advanced Drug Delivery Strategies in Geriatric Patients with Polypharmacy: Integrating Pharmacokinetics, Personalized Medicine, and Emerging Technologies.Journal of clinical medicine · 2026Review
- Machine Learning Prediction of Prolonged Length of Stay in Older Patients with Lung Cancer: A Multicenter Study Using XGBoost with SHAP Interpretation.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With global population aging, the prevalence of multimorbidity among older adults has risen sharply. This growing complexity challenges traditional single-disease-oriented healthcare models, leading to fragmented care, increased polypharmacy risks, and poor clinical outcomes. Precision medicine, integrating genomic, phenotypic, and behavioral data, offers a promising avenue for individualized care in this context. Concurrently, artificial intelligence (AI) has emerged as a powerful enabler of precision medicine by facilitating large-scale data analysis, real-time risk prediction, and multimodal data integration. This review summarizes recent advances in the application of AI-enabled precision medicine for managing geriatric multimorbidity, providing a theoretical and practical framework for integrating AI-enabled care. It highlights the need for interdisciplinary collaboration, regulatory innovation, and equity-focused design to transform multimorbidity management in aging societies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.